- Home
- RLAY
as 11-15-2024 4:00pm EST
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 1.1B | IPO Year: | 2020 |
| Target Price: | $20.88 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.03 - $12.14 | Next Earning Date: | 11-06-2024 |
| Revenue: | $10,006,000 | Revenue Growth: | -61.22% |
| Revenue Growth (this year): | -59.48% | Revenue Growth (next year): | -93.56% |
Stock Insider Trading Activity of Relay Therapeutics Inc. (RLAY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bergstrom Donald A | RLAY | President, R&D | Oct 28 '24 | Sell | $6.06 | 2,688 | $16,289.28 | 520,745 | |
| Adams Brian | RLAY | Chief Legal Officer | Oct 28 '24 | Sell | $6.06 | 1,632 | $9,889.92 | 321,907 | |
| Catinazzo Thomas | RLAY | Chief Financial Officer | Oct 28 '24 | Sell | $6.02 | 9,102 | $54,905.12 | 311,496 | |
| Bergstrom Donald A | RLAY | President, R&D | Sep 27 '24 | Sell | $7.51 | 648 | $4,866.48 | 520,745 | |
| Adams Brian | RLAY | Chief Legal Officer | Sep 27 '24 | Sell | $7.51 | 295 | $2,215.45 | 321,907 | |
| Catinazzo Thomas | RLAY | Chief Financial Officer | Sep 27 '24 | Sell | $7.48 | 6,457 | $48,183.97 | 311,496 | |
| Rahmer Peter | RLAY | See remarks | Sep 27 '24 | Sell | $7.51 | 245 | $1,839.95 | 391,684 |
Latest Relay Therapeutics Inc. News
RLAY Breaking Stock News: Dive into RLAY Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
Relay Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
11 days ago
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
GlobeNewswire
18 days ago
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024
Simply Wall St.
20 days ago
Institutional owners may consider drastic measures as Relay Therapeutics, Inc.'s (NASDAQ:RLAY) recent US$67m drop adds to long-term losses
Zacks
2 months ago
Strength Seen in Relay Therapeutics (RLAY): Can Its 6.7% Jump Turn into More Strength?
Motley Fool
2 months ago
Why Relay Therapeutics Plummeted by Nearly 14% Today
MT Newswires
2 months ago
Sector Update: Health Care
MT Newswires
2 months ago
Relay Therapeutics Prices $200 Million Common Stock Offering; Shares Fall Pre-Bell
Compare RLAY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RLAY Relay Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.